Published in J Clin Oncol on February 22, 2011
Longitudinal patient-reported performance status assessment in the cancer clinic is feasible and prognostic. J Oncol Pract (2011) 1.17
Using the EORTC-QLQ-C30 in clinical practice for patient management: identifying scores requiring a clinician's attention. Qual Life Res (2013) 0.93
Methadone induction in primary care for opioid dependence: a pragmatic randomized trial (ANRS Methaville). PLoS One (2014) 0.86
Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients' supportive care needs. Qual Life Res (2014) 0.83
PRO-ONKO-selection of patient-reported outcome assessments for the clinical use in cancer patients-a mixed-method multicenter cross-sectional exploratory study. Support Care Cancer (2015) 0.77
Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain. Health Qual Life Outcomes (2016) 0.75
Patient-reported symptom distress, and most bothersome issues, before and during cancer treatment. Patient Relat Outcome Meas (2016) 0.75
Durable usage of patient-reported outcome measures in clinical practice to monitor health-related quality of life in head and neck cancer patients. Support Care Cancer (2017) 0.75
Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA (2005) 20.53
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Methods to explain the clinical significance of health status measures. Mayo Clin Proc (2002) 7.00
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA (2002) 5.30
Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA (2013) 4.98
Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol (2003) 4.57
Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res (2004) 4.33
Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med (2008) 4.33
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med (2016) 3.99
Incidents relating to the intra-hospital transfer of critically ill patients. An analysis of the reports submitted to the Australian Incident Monitoring Study in Intensive Care. Intensive Care Med (2004) 3.81
Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr (2002) 3.55
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol (2007) 3.23
Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol (2006) 3.09
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol (2007) 3.05
In the wake of the 2003 and 2011 duty hours regulations, how do internal medicine interns spend their time? J Gen Intern Med (2013) 3.03
The relationship between a dementia diagnosis, chronic illness, medicare expenditures, and hospital use. J Am Geriatr Soc (2004) 2.89
Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. J Clin Oncol (2005) 2.71
Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol (2008) 2.68
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int (2011) 2.68
Trends in follow-up and preventive care for colorectal cancer survivors. J Gen Intern Med (2008) 2.64
Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes (2006) 2.48
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol (2011) 2.46
Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 2.45
Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol (2005) 2.42
Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res (2011) 2.42
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med (2009) 2.36
Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol (2009) 2.35
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29
Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol (2009) 2.26
The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease. J Clin Epidemiol (2002) 2.25
A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis (2005) 2.25
Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol (2008) 2.23
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
Evaluation of two methods for quality improvement in intensive care: facilitated incident monitoring and retrospective medical chart review. Crit Care Med (2003) 2.17
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res (2006) 2.15
Reducing health care hazards: lessons from the commercial aviation safety team. Health Aff (Millwood) (2009) 2.11
Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer (2006) 2.10
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol (2010) 2.07
Changes in patient satisfaction related to hospital renovation: experience with a new clinical building. J Hosp Med (2015) 2.06
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Chronic medical illness, depression, and use of acute medical services among Medicare beneficiaries. Med Care (2004) 2.00
Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol (2003) 2.00
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med (2012) 2.00
Sleep disturbance in cancer patients. Soc Sci Med (2002) 1.99
Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics (2004) 1.98
Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates. Cancer (2011) 1.98
Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr (2002) 1.97
The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer (2005) 1.97
ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res (2013) 1.96
An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer (2008) 1.95
Application of a propensity score approach for risk adjustment in profiling multiple physician groups on asthma care. Health Serv Res (2005) 1.92
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol (2008) 1.91
Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care (2010) 1.88
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. Eur J Cancer (2012) 1.87
NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86
The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy. Med Care (2012) 1.84
An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer (2010) 1.84
A systematic review of web-based interventions for patient empowerment and physical activity in chronic diseases: relevance for cancer survivors. J Med Internet Res (2013) 1.82
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer (2011) 1.80
Recent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the Surveillance, Epidemiology, and End Results Program. Urology (2009) 1.80
Asthma in older patients: factors associated with hospitalization. Arch Intern Med (2002) 1.77
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76
The impact of anemia on energy and physical functioning in individuals with AIDS. Arch Intern Med (2005) 1.75
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther (2006) 1.74
Further insight into the perception of quantitative information: judgments of gist in treatment decisions. Med Decis Making (2007) 1.73
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol (2008) 1.71
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol (2012) 1.68
Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors--a meta-analysis. Psychooncology (2011) 1.68
Do the SF-36 and WHOQOL-BREF measure the same constructs? Evidence from the Taiwan population*. Qual Life Res (2006) 1.67
PatientViewpoint: a website for patient-reported outcomes assessment. Qual Life Res (2009) 1.64
Optimizing measurement of self-reported adherence with the ACTG Adherence Questionnaire: a cross-protocol analysis. J Acquir Immune Defic Syndr (2007) 1.62
Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach. Eur J Cancer (2007) 1.62
Comparing higher order models for the EORTC QLQ-C30. Qual Life Res (2011) 1.60
Gender differences in health-related quality of life in patients with HIV/AIDS. Qual Life Res (2005) 1.60
Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression. Prostate (2011) 1.58
Health care workers as second victims of medical errors. Pol Arch Med Wewn (2011) 1.58
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2008) 1.56
A system factors analysis of airway events from the Intensive Care Unit Safety Reporting System (ICUSRS). Crit Care Med (2004) 1.56
Methodological quality of patient-reported outcome research was low in complementary and alternative medicine in oncology. J Clin Epidemiol (2006) 1.55
The course of neurocognitive functioning in high-grade glioma patients. Neuro Oncol (2006) 1.55
Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer (2011) 1.52
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel. Prostate (2013) 1.52
Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine. Clin Infect Dis (2004) 1.52
Health related quality of life in men with prostate cancer. J Urol (2003) 1.51
Critical pathway effectiveness: assessing the impact of patient, hospital care, and pathway characteristics using qualitative comparative analysis. Health Serv Res (2005) 1.51
Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res (2006) 1.50
Cost-effectiveness of cognitive behavioral therapy and physical exercise for alleviating treatment-induced menopausal symptoms in breast cancer patients. J Cancer Surviv (2014) 1.49
Impact of bariatric surgery on health care utilization and costs among patients with diabetes. Med Care (2012) 1.49
A system factors analysis of "line, tube, and drain" incidents in the intensive care unit. Crit Care Med (2005) 1.48
Older patients with diverticulitis have low recurrence rates and rarely need surgery. Surgery (2011) 1.48
Parent perspectives of health related quality of life for adolescents with bladder exstrophy-epispadias as measured by the child health questionnaire-parent form 50. J Urol (2010) 1.47